CDC Issues Recommendations for 2026-2027 Influenza Vaccines

The Centers for Disease Control and Prevention (CDC) has issued its recommendations for use of the seasonal 2026-2027 influenza (flu) vaccines, including:

• Routine annual flu vaccination recommendations remain the same as described in the July 2025 immunization schedule.

• All persons should receive a U.S. Food and Drug Administration-licensed age-appropriate influenza vaccine with the exception that solid organ transplant recipients aged 18 through 64 years who are receiving immunosuppressive medication regimens may receive either HD-IIV3 or aIIV3 as acceptable options (without a preference over other age-appropriate IIV3s or RIV3).

• There are no preferential recommendations for the use of any one influenza vaccine over another when more than one licensed and recommended vaccine is available, except for persons age 65 years and older for whom HD-IIV3, RIV3 or aIIV3 are preferentially recommended.

More information about the specific recommendations can be found at www.cdc.gov/flu/hcp/vax-summary/seasonal-influenza-vaccines.html.

BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.